Pictet Asset Management Holding SA Sells 19,613 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Pictet Asset Management Holding SA cut its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 1.1% in the 4th quarter, HoldingsChannel reports. The fund owned 1,768,917 shares of the company’s stock after selling 19,613 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Nurix Therapeutics were worth $33,326,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in NRIX. US Bancorp DE boosted its stake in shares of Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after buying an additional 842 shares during the period. Quarry LP boosted its holdings in shares of Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after acquiring an additional 2,435 shares in the last quarter. Bellevue Group AG acquired a new stake in shares of Nurix Therapeutics during the third quarter valued at about $180,000. EP Wealth Advisors LLC acquired a new stake in Nurix Therapeutics during the 3rd quarter worth approximately $240,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Nurix Therapeutics in the fourth quarter worth $209,000.

Analyst Upgrades and Downgrades

NRIX has been the topic of several analyst reports. BMO Capital Markets initiated coverage on Nurix Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $35.00 target price on the stock. HC Wainwright upped their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Stephens reaffirmed an “overweight” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Needham & Company LLC dropped their price objective on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Finally, Leerink Partners started coverage on Nurix Therapeutics in a research note on Monday, March 17th. They issued a “market perform” rating and a $16.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $30.88.

Insider Buying and Selling

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the transaction, the insider now directly owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Houte Hans Van sold 2,811 shares of Nurix Therapeutics stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now owns 39,549 shares in the company, valued at approximately $785,047.65. The trade was a 6.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock worth $213,449 over the last ninety days. 7.20% of the stock is owned by corporate insiders.

Nurix Therapeutics Trading Down 3.2 %

Nurix Therapeutics stock opened at $12.15 on Monday. The firm has a market capitalization of $922.03 million, a price-to-earnings ratio of -4.20 and a beta of 2.18. The firm has a 50 day simple moving average of $16.34 and a 200 day simple moving average of $20.35. Nurix Therapeutics, Inc. has a 1-year low of $11.90 and a 1-year high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.